Tawee Tanvetyanon

Moffitt Cancer Center — United States

Medicine · Health Sciences

40h-index7.8kcitations273works34.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(102), Cancer Immunotherapy and Biomarkers(70), Lung Cancer Research Studies(49), Lung Cancer Diagnosis and Treatment(45), Head and Neck Cancer Studies(27)

Publications273 total

Timing of Durvalumab Consolidation and Survival in Non–Small Cell Lung Cancer: A Population-Based Analysis
JCO Oncology Practice·2025
Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use
Clinical Lung Cancer·2025
Relationship between PD-L1 Expression and Outcomes of Salvage Treatment Following Durvalumab Consolidation
Clinical Lung Cancer·2025
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025
Journal of the National Comprehensive Cancer Network·2025· 15 cited
Real World Safety of Tarlatamab Step-Up Dosing in Extensive Stage Small Cell Lung Cancer
Journal of Thoracic Oncology·2025· 1 cited
Timeliness of Newer Targeted Therapy and Survival in Lung Cancer: A Population-Based Analysis
JCO Oncology Practice·2025
Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network·2025· 11 cited
S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
JTO Clinical and Research Reports·2024· 3 citedOpen Access
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve <i>EGFR</i> -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
Journal of Clinical Oncology·2024· 34 citedOpen Access
Systemic Therapy Options for Peritoneal Mesothelioma
Journal of the National Comprehensive Cancer Network·2024· 3 cited
MA11.09 Phase II Trial of Atezolizumab Plus Cobimetinib in PD-(L)1 Inhibitor Resistant NSCLC: NCI ETCTN Study 10166
Journal of Thoracic Oncology·2024
Association between Infection and Calculated Globulin Level among Patients with Thymic Epithelial Tumor
Journal of Clinical Medicine·2024· 1 citedOpen Access
Surgery and Stereotactic Radiotherapy for Stage I Small-Cell Lung Carcinoma: A 25-Year Experience
Clinical Lung Cancer·2024· 2 citedOpen Access
Timing of EGFR or ALK inhibitor initiation and survival among patients with advanced NSCLC.
Journal of Clinical Oncology·2024
S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma.
Journal of Clinical Oncology·2024· 5 cited
A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC).
Journal of Clinical Oncology·2024· 1 cited
Non–Small Cell Lung Cancer, Version 4.2024
Journal of the National Comprehensive Cancer Network·2024· 617 cited
Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis
Clinical Lung Cancer·2024· 2 cited
Abstract CT052: A phase IB study of mRNA-based active cancer vaccine, BI1361849, combined with durvalumab and tremelimumab immunotherapy in patients with non-small cell lung cancer (NSCLC)
Cancer Research·2024· 5 cited
Mesothelioma: Pleural, Version 1.2024
Journal of the National Comprehensive Cancer Network·2024· 24 citedOpen Access
page 1 of 14Next →

Frequent Co-authors

Eric B. Haura(15), Alberto Chiappori(14), Scott Antonia(13), Jhanelle E. Gray(13), Gerold Bepler(12), Ben Creelan(11), Charles C. Williams(9), Lary A. Robinson(7), Michael J. Schell(7), Tapan Padhya(7), George R. Simon(6), Judith C. McCaffrey(6), Andy Trotti(6), Theresa A. Boyle(5), Douglas E. Wood(4), Thomas J. Dilling(4), Andreas Saltos(4), Dung‐Tsa Chen(4), Ronald C. DeConti(4), Ram Thapa(4)